Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020

20200622a – Transgene PR AACR 3 posters

Published 22 June 2020
Categorized as 2020, BT-001, Invir.IO, Myvac, Press release

Combined General Meeting of May 27, 2020

20200527 TG AGM 2020

Published 27 May 2020
Categorized as 2020, Press release

Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors

20200515 BT-001_AACR curtain raiser EN

Published 15 May 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050

20200515_AACR myvac curtain raiser EN

Published 15 May 2020
Categorized as 2020, Myvac, Press release, TG4050

Transgene reports Q1 2020 financial position and business update

20200506 TG FINANCIAL T1- US

Published 6 May 2020
Categorized as 2020, Press release

Vaxxel acquires Transgene’s DuckCelt®-T17 cell line to develop industrial-scale vaccines against respiratory viruses

20200504 – TG Vaxxell EN

Published 4 May 2020
Categorized as 2020, Press release

Availability of Transgene’s 2019 Universal Registration Document and update on the effect of Covid-19

20200402PR-EN availability URD 2019

Published 3 April 2020
Categorized as 2020, Press release

Availability of Preparatory Documents for the Combined General Meeting of May 27, 2020

20200403 – availability doc AG – EN

Published 3 April 2020
Categorized as 2020, Press release

BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment

Poster BT-001Marchand, Semmrich, Fend et al. Immuno-Oncology summit Download the poster here Poster Presentation

Published 11 March 2020
Categorized as 2020, BT-001, Publication

Major R&D milestones achieved in 2019 and strong clinical activity in 2020

20200311 Resultats 2019 EN

Published 11 March 2020
Categorized as 2020, Press release

Posts pagination

Newer posts Page 1 … Page 26 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu